Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
VX-950
Cat No.
CEI-0220
Description
VX-950 is a potent, small molecule, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3.4A serine protease with IC50 of 350 nM.
Alias
VX950, Telaprevir, LY-570310, MP-424
CAS No.
402957-28-2
Molecular Weight
679.85
Purity
0.99
Storage
2 years -20centigrade Powder
Synonyms
VX950, Telaprevir, LY-570310, MP-424
Targets
HCV NS3-4A serine protease
Molecular Formula
C36H53N7O6
Chemical Name
(3S,3aS, 6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl] amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1, 2-dioxohexan-3-yl]-3,3a,4,5,6, 6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
Solubility
DMSO 136 mg/ml, Water
In vitro
VX-950 is a potent, small molecule, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3.4A serine protease. Although competitive with the peptide substrate in the active site, VX-950 exhibits apparent noncompetitive inhibition as a result of its tight binding properties and time-dependent inhibition mechanism. Incubation of the HCV Con1 subgenomic replicon cells with VX-950 results in a concentration-dependent decline of the HCV RNA level. The dominant resistance mutation observed against VX-950 was a substitution of Ala156 in the HCV NS3 protease domain with a serine. VX-950 demonstrates excellent antiviral activity both in genotype 1b HCV replicon cells with IC50 of 354 nM and in human fetal hepatocytes infected with genotype 1a HCV-positive patient sera with IC50 of 280 nM. VX-950 forms a covalent but reversible complex with the genotype 1a HCV NS3-4A protease in a slow-on, slow-off process with a steady-state inhibition constant Ki of 7 nM.
Download
Download Datasheet